These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25410773)

  • 1. Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI).
    So W; Kuti JL; Nicolau DP
    Infect Dis Ther; 2014 Dec; 3(2):269-79. PubMed ID: 25410773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic Cefazolin Dosing in Women With Body Mass Index >35 kg·m-2 Undergoing Cesarean Delivery: A Pharmacokinetic Study of Plasma and Interstitial Fluid.
    Eley VA; Christensen R; Ryan R; Jackson D; Parker SL; Smith M; van Zundert AA; Wallis SC; Lipman J; Roberts JA
    Anesth Analg; 2020 Jul; 131(1):199-207. PubMed ID: 32250982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and pharmacodynamics of cefazolin using total and unbound serum concentrations in patients with high body weight.
    Chung EK; Cheatham SC; Healy DP; Stock AH; Utley S; Campion M; Murrey T; Gesenhues AM; Jeffery J; Kays MB
    Int J Antimicrob Agents; 2023 Apr; 61(4):106751. PubMed ID: 36758780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and Interstitial Fluid Pharmacokinetics of Prophylactic Cefazolin in Elective Bariatric Surgery Patients.
    Ryan RL; Jackson D; Hopkins G; Eley V; Christensen R; Van Zundert AAJ; Wallis SC; Lipman J; Parker SL; Roberts JA
    Antimicrob Agents Chemother; 2022 Jul; 66(7):e0041922. PubMed ID: 35762797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis.
    Brill MJ; Houwink AP; Schmidt S; Van Dongen EP; Hazebroek EJ; van Ramshorst B; Deneer VH; Mouton JW; Knibbe CA
    J Antimicrob Chemother; 2014 Mar; 69(3):715-23. PubMed ID: 24214905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections.
    Hamada Y; Kuti JL; Nicolau DP
    J Antimicrob Chemother; 2015 Jul; 70(7):2064-7. PubMed ID: 25802284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery.
    Grupper M; Kuti JL; Swank ML; Maggio L; Hughes BL; Nicolau DP
    J Clin Pharmacol; 2017 Jun; 57(6):712-719. PubMed ID: 27925657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue pharmacokinetics of cefazolin in patients with lower limb infections.
    Bhalodi AA; Housman ST; Shepard A; Nugent J; Nicolau DP
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5679-83. PubMed ID: 24041887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetic Modeling and Probability of Target Attainment of Ceftaroline in Brain and Soft Tissues.
    Helfer VE; Zavascki AP; Zeitlinger M; de Araújo BV; Dalla Costa T
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0074122. PubMed ID: 36005769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
    Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
    J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
    Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humanized tissue pharmacodynamics of cefazolin against commonly isolated pathogens in skin and skin structure infections.
    Jain JG; Housman ST; Nicolau DP
    J Antimicrob Chemother; 2014 Sep; 69(9):2443-7. PubMed ID: 24827890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Ampicillin in Neonates with Hypoxemic-Ischemic Encephalopathy in the Setting of Controlled Hypothermia.
    Cies JJ; Fugarolas KN; Moore WS; Mason RW; Menkiti OR
    Pharmacotherapy; 2017 Apr; 37(4):456-463. PubMed ID: 28226400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches.
    Barbour AM; Schmidt S; Zhuang L; Rand K; Derendorf H
    Int J Antimicrob Agents; 2014 Jan; 43(1):60-7. PubMed ID: 24183800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction.
    Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperacillin pharmacokinetics and target attainment in children with cancer and fever: Can we optimize our dosing strategy?
    Maarbjerg SF; Thorsted A; Kristoffersson A; Friberg LE; Nielsen EI; Wang M; Brock B; Schrøder H
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27654. PubMed ID: 30740885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients.
    Roberts JA; Udy AA; Jarrett P; Wallis SC; Hope WW; Sharma R; Kirkpatrick CM; Kruger PS; Roberts MS; Lipman J
    J Antimicrob Chemother; 2015 May; 70(5):1495-502. PubMed ID: 25608584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetic and Pharmacodynamic Target Attainment Analysis of Cefazolin in the Serum and Hip Joint Capsule of Patients Undergoing Total Hip Arthroplasty.
    Komatsu T; Natsume Y; Uchiyama K; Ikeda S; Tomoda Y; Takayama Y; Takaso M; Hanaki H; Atsuda K
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
    Ong CT; Kuti JL; Nicolau DP;
    Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of colistimethate sodium in critical patients: an in vitro study by using of Monte Carlo simulation].
    Pan A; Mei Q; Yang T; Gao X; Lu H; Ye Y; Li J; Liu B
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 May; 29(5):385-389. PubMed ID: 28524024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.